Q4 FY-20

January 3, 2020
Credit Rating from ICRA
Initial Intimation Letter
Revised Intimation Letter

December 31, 2019
Notice of Board meeting
Reconciliation of Share Capital as on December 31, 2019.
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended December 31, 2019
Corporate Governance Report as on December 31, 2019.
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended December 31, 2019
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended December 31, 2019.
Closure of Trading Window.

November 15, 2019
September 30, 2019 Related Party disclosures for half year ended September 30, 2019.

November 2, 2019
ANDA approval from USFDA for Unichem’s Atenolol Tablets USP

September 30, 2019
Related Party disclosures for half year ended September 30, 2019.
Reconciliation of Share Capital as on September 30, 2019.
Notice of Board meeting
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended September 30, 2019.
Corporate Governance Report as on September 30, 2019
Compliance Certificate – Regulation 7(3) as on September 30, 2019
Certificate under regulation 40(9) & 40 (10) as on September 30, 2019
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended September 30, 2019
Closure of Trading Window

September 20, 2019
USFDA approval for Kolhapur plant

September 6, 2019
USFDA approval for Pithampur plant

August 28, 2019
ANDA approval from USFDA for Solifenacin Succinate Tablets, 5 mg and 10 mg.

August 26, 2019
USFDA approval for the Company’s Ghaziabad plant

August 13, 2019
ANDA approval from USFDA for Unichem’s Tramadol Hydrochloride Tablets

August 12, 2019
ANDA approval from USFDA for Unichem’s Chlorthalidone Tablets

August 1, 2019
Appointment of Company Secretary and Compliance Officer
Changes in KMP for dissemination of Material Information

July 31, 2019
Retirement of Company Secretary

July 27, 2019
Outcome of 56TH AGM
Proceedings
Voting results and Scrutinizer’s report

July 5, 2019
Setting up of a Wholly Owned Subsidiary in China

Q1 FY-20

June 30, 2019
Reconciliation of Share Capital as on June 30, 2019.
Certificate under regulation 74(5) of the SEBl (Depositories and Participants) Regulations. 2018 for the quarter ended June 30, 2019.
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended June 30, 2019.
Corporate Governance Report as on June 30, 2019.
Closure of Trading Window
Notice of Board Meeting

May 7, 2019
Tentative ANDA approval from USFDA for Unichem’sCetirizine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets

May 3, 2019
Board meeting May 03, 2019
Update on board meeting

Q4 FY-19

March 28, 2019

Outcome of the meeting held on 28.3.2019.

March 27, 2019

Final ANDA Approval from USFDA for Unichem’s Tadalafil Tablets 2.5 mg, 5 mg, 10 mg and 20 mg.

March 13, 2019

ANDA approval from USFDA for Unichem’s Allopurinol Tablets

March 11, 2019

Ghaziabad Facility is inspected by USFDA

February 26, 2019

Intimation of Appeal against the E.U.

Q3 FY-19

December 31, 2018

Notice of Board meeting published in Newspaper
Notice of Board meeting
Corporate Governance Report as on December 31, 2018
Reconciliation of Share Capital as on December 31, 2018
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended December 31, 2018

December 21, 2018

ANDA approval from USFDA for Unichem’s Pramipexole Dihydrochloride Tablets

December 13, 2018

Updation on the EU commission Litigation

December 11, 2018

Tentative ANDA Approval from USFDA for, Unichem’s Tadalafil Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg.

November 14, 2018

Postal Ballot Newspaper Advertisement

November 2, 2018

Strategic Investment In Optimus Drugs Private Limited and Optrix Laboratories Private Limited

October 22, 2018

EIR for Unichem’s API manufacturing facilities at Pithampur and Roha

Q2 FY-19

September 30, 2018

Notice of Board Meeting

Corporate Governance Report as on September 30, 2018

Reconciliation of Share Capital as on September 30, 2018

Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter ended September 30, 2018

Compliance Certificate – Regulation 7(3) as on September 30, 2018

Certificate under regulation 40(9) & 40 (10) as on September 30, 2018

September 24, 2018

Credit Rating from ICRA

September 3, 2018

Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

August 7, 2018

Grant of Stock Options under the Unichem Employee Stock Option Scheme 2018

July 28, 2018 – 55th AGM

Outcome of 55th AGM – Scrutinizer’s Report

Outcome of 55TH AGM – Results under Regulation 44 of the Listing Regulations

Proceedings of 55th AGM

NOTICE OF 55thANNUAL GENERAL MEETING, REMOTE E-VOTING AND BOOK CLOSURE

July 4, 2018

Receipt of ANDA approval from USFDA for Unichem’s Montelukast Chewable Tablets, 4 mg and 5 mg.

July 3, 2018

Financial Statements of Subsidiaries for the financial year ended 2017-2018

Niche Genercis Limited
Unichem Farmaceutica Do Brazil Ltda
Unichem Laboratories Limited- Ireland
Unichem Pharmaceutical (USA), Inc.
Unichem SA (Propreitary) Limited

Q1 FY-19

June 30, 2018

Notice of Board Meeting
Corporate Governance Report as on June 30, 2018
Reconciliation of Share Capital as on June 30, 2018
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter

June 20, 2018

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Unichem has entered into a settlement agreement with Eli Lilly & Company and ICOS Corporation to resolve their patent litigation in the United States District Court for the District of New Jersey regarding Unichem’s Abbreviated New Drug Application for generic tadalafil (Cialis®). Under the settlement agreement, Unichem expects to launch its generic tadalafil product in the United States on or not before March 26, 2019 under certain circumstances.

June 6, 2018

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Unichem’s formulation manufacturing facility at Ghaziabad has received an Establishment Inspection Report (EIR) from USFDA indicating closure of inspection. The inspection was conducted by FDA in April 2018.

May 29, 2018
Notice to Stock Exchanges
News paper advertisement
Notice Sakhal
Notice Business Standard

Q4 FY-18

March 31, 2018
Familiarization Programme for the year 2018
Outcome of Board meeting

February 5, 2018
Interim Audited Consolidated Financial Statements for the nine months period ended December 31, 2017 and Record date ascertaining the Shareholders eligible for Buyback.
Newspaper publication of the Notice for Board meeting scheduled on 5.2.2018
Notice of Board meeting scheduled on February 5, 2018

January 3, 2018
Notice of BuyBack

Q3 FY-18

December 31, 2017
Reconciliation of Share Capital as on December 31, 2017
Corporate Governance Report as on December 31, 2017
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter December 31, 2017
Notice of Board Meeting

December 14, 2017
Press Release – Unichem Laboratories Limited, completes the Sale and Transfer of Identified Business to Torrent Pharmaceuticals Limited

November 3, 2017
Revised Press Release on Sale and Transfer of Identified Business
Disclosure Under Regulation 30 of LODR on Sale and Transfer of Identified Business and Press Release

Q2 FY-18

September 30, 2017
Newspaper advertisement of the Unaudited financial results for the quarter and half year ended September 30, 2017
Notice of Board Meeting
Board meeting postponed
Notice of Board Meeting
Reconciliation of Share Capital as on September 30, 2017
Corporate Governance Report as on September 30, 2017
Certificate under regulation 40(9) & 40 (10) as on September 30, 2017
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter September 30, 2017
Compliance Certificate – Regulation 7(3) as on September 30, 2017

July 22, 2017
Proceedings of the 54th Annual General Meeting
54th AGM Voting Results and Scrutinizer’s Report

Q1 FY-18

June 30, 2017
Newspaper Advertisement of Unaudited Standalone Financial results (Business Standard & Sakal)
Notice of Board Meeting
Reconciliation of Share Capital as on June 30, 2017
Corporate Governance Report as on June 30, 2017
Statement of Investor Complaints Pursuant to Regulation 13(3) for Quarter June 30, 2017

June 26, 2017

Notice and Newspaper Advertisement of 54th Annual General Meeting, remote E-voting and Book Closure

April 17, 2017

Intimation of Transfer of Equity Shares of the Company to Investor Education and Protection Fund (IEPF) Demat Account.

April 17, 2017

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Company has received ANDA approval from the United States Food and Drug Administration (USFDA) for Piroxicam Capsules USP 10mg & 20mg, which are therapeutically equivalent to Feldene Capsules 10mg & 20mg of Pfizer, Inc. Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) indicated for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA). For the relief of rheumatoid arthritis and osteoarthritis, the dosage is 20 mg given orally once daily. If desired, the daily dose may be divided. Usually lowest effective dosage for the shortest duration, consistent with individual patient treatment goals is recommended. The product will be commercialized from Unichem’s Goa plant. Active Pharmaceutical Ingredient will also be made in house at Roha API Plant.